OpenBit ResearchOpenBit
中文

What's driving argenx SE (ARGX)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Efgartigimod Myositis Expansion Durability

Why it matters now

Successful myositis expansion would broaden efgartigimod's addressable market and revenue contribution for argenx.

What would break the thesis

Further analysis overturns the overall ALKIVIA primary-endpoint result or shows the observed benefit is not clinically meaningful.

Research drivers

  • Efgartigimod Myositis Expansion Durability

    Bullish · Active · Updated

    The overall myositis expansion signal is strengthened by sustained Week 52 efficacy, a significant IMNM result, and consistent treatment-effect contributions across both IMNM and DM, while subgroup breadth remains uncertain.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • In DM patients, efgartigimod produced a 14.5-point improvement over placebo, with mean TIS scores of 51.51 versus 36.96, but statistical significance was not reached in the smaller group.

    Relayed by: Benzinga · Event date on record:

  • The ALKIVIA study met its primary endpoint, with a p-value of 0.0011.

    Relayed by: Benzinga · Event date on record:

  • Argenx reported positive topline results from its Phase 3 ALKIVIA study of efgartigimod alfa and hyaluronidase-qvfc in adults with autoimmune myositis.

    Relayed by: Benzinga · Event date on record:

  • All six core set measures of TIS favored efgartigimod over placebo in both IMNM and DM, covering muscle strength, everyday physical function, and disease activity beyond the muscle.

    Relayed by: Benzinga · Event date on record:

  • In IMNM patients, the primary endpoint at 52 weeks was met, with efgartigimod producing a 14.8-point greater improvement over placebo and mean TIS scores of 45.05 versus 30.24.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.